Cargando…

A Novel Interaction Between HER2/neu and Cyclin E in Breast Cancer

HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. Since both are involved in cell cycle regulation we investigated whether there was a direct interaction between the two. HER2 and cyclin E expression levels were determined in 395 breast cancer patients. Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mittendorf, Elizabeth A., Liu, Yanna, Tucker, Susan L., McKenzie, Tamra, Qiao, Na, Akli, Said, Biernacka, Anna, Liu, Yan, Meijer, Laurent, Keyomarsi, Khandan, Hunt, Kelly K.
Formato:	Texto
Lenguaje:	English
Publicado:	2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900397/ https://www.ncbi.nlm.nih.gov/pubmed/20453888 http://dx.doi.org/10.1038/onc.2010.151

Ejemplares similares

Low-molecular-weight cyclin E: the missing link between biology and clinical outcome
por: Akli, Said, et al.
Publicado: (2004)

The Serine Protease Inhibitor Elafin Maintains Normal Growth Control by Opposing the Mitogenic Effects of Neutrophil Elastase
por: Caruso, Joseph A., et al.
Publicado: (2014)

LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers
por: Lulla, Amriti R., et al.
Publicado: (2021)

PKC iota promotes ovarian tumor progression through deregulation of cyclin E
por: Nanos-Webb, Angela, et al.
Publicado: (2015)

LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients
por: Duong, MyLinh T., et al.
Publicado: (2012)

Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis
por: Dong, Yiyu, et al.
Publicado: (2014)

Targeting the cell cycle for prognosis and therapy of breast cancer
por: Keyomarsi, K, et al.
Publicado: (2005)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer
por: Alexander, Angela, et al.
Publicado: (2017)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer
por: Hunt, Kelly K, et al.
Publicado: (2013)

Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age
por: Johnston, Simon J., et al.
Publicado: (2020)

Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer
por: Mull, Benjamin B., et al.
Publicado: (2020)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
por: Greene, Julia, et al.
Publicado: (2014)

Leveraging MYC as a therapeutic treatment option for TNBC
por: Carey, Jason P.W., et al.
Publicado: (2018)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
por: Vijayaraghavan, Smruthi, et al.
Publicado: (2017)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Expression of HER-2/neu in Oral Squamous Cell Carcinoma
por: Mirza, Sana, et al.
Publicado: (2020)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma
por: Liu, Tieju, et al.
Publicado: (2013)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span
por: Provinciali, Mauro, et al.
Publicado: (2017)

Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration
por: Chen, Xian, et al.
Publicado: (2021)

Factors Influencing Lymph Node Positivity in HER2/neu+ Breast Cancer Patients
por: Englander, Katherine, et al.
Publicado: (2023)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles
por: Moghadam, Sonia Javan, et al.
Publicado: (2011)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings
por: Babashahi, Mashaallah, et al.
Publicado: (2013)

Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer
por: Keay, Tyler, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3ur88crugfe1c9lgsgdomalpka